Health Catalyst Statistics
Total Valuation
HCAT has a market cap or net worth of $464.41 million. The enterprise value is $404.82 million.
Important Dates
The next confirmed earnings date is Wednesday, November 6, 2024, after market close.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
HCAT has 60.47 million shares outstanding. The number of shares has increased by 5.66% in one year.
| Shares Outstanding | 60.47M |
| Shares Change (YoY) | +5.66% |
| Shares Change (QoQ) | +1.22% |
| Owned by Insiders (%) | 2.79% |
| Owned by Institutions (%) | 90.65% |
| Float | 58.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 18.55 |
| PS Ratio | 1.49 |
| Forward PS | 1.41 |
| PB Ratio | 1.29 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.35 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.18, with a Debt / Equity ratio of 0.70.
| Current Ratio | 1.18 |
| Quick Ratio | 1.15 |
| Debt / Equity | 0.70 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.19 |
Financial Efficiency
Return on equity (ROE) is -23.15% and return on invested capital (ROIC) is -7.48%.
| Return on Equity (ROE) | -23.15% |
| Return on Assets (ROA) | -6.58% |
| Return on Capital (ROIC) | -7.48% |
| Revenue Per Employee | $230,371 |
| Profits Per Employee | -$66,498 |
| Employee Count | 1,300 |
| Asset Turnover | 0.42 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, HCAT has paid $385,000 in taxes.
| Income Tax | 385,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.05% in the last 52 weeks. The beta is 1.32, so HCAT's price volatility has been higher than the market average.
| Beta (5Y) | 1.32 |
| 52-Week Price Change | +1.05% |
| 50-Day Moving Average | 7.96 |
| 200-Day Moving Average | 7.47 |
| Relative Strength Index (RSI) | 42.05 |
| Average Volume (20 Days) | 464,643 |
Short Selling Information
The latest short interest is 2.61 million, so 4.32% of the outstanding shares have been sold short.
| Short Interest | 2.61M |
| Short Previous Month | 2.65M |
| Short % of Shares Out | 4.32% |
| Short % of Float | 4.44% |
| Short Ratio (days to cover) | 5.92 |
Income Statement
In the last 12 months, HCAT had revenue of $299.48 million and -$86.45 million in losses. Loss per share was -$1.49.
| Revenue | 299.48M |
| Gross Profit | 137.38M |
| Operating Income | -74.48M |
| Pretax Income | -86.06M |
| Net Income | -86.45M |
| EBITDA | -41.70M |
| EBIT | -74.48M |
| Loss Per Share | -$1.49 |
Full Income StatementBalance Sheet
The company has $308.26 million in cash and $248.67 million in debt, giving a net cash position of $59.59 million or $0.99 per share.
| Cash & Cash Equivalents | 308.26M |
| Total Debt | 248.67M |
| Net Cash | 59.59M |
| Net Cash Per Share | $0.99 |
| Equity (Book Value) | 357.00M |
| Book Value Per Share | 5.94 |
| Working Capital | 58.04M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$4.05 million and capital expenditures -$902,000, giving a free cash flow of -$4.95 million.
| Operating Cash Flow | -4.05M |
| Capital Expenditures | -902,000 |
| Free Cash Flow | -4.95M |
| FCF Per Share | -$0.08 |
Full Cash Flow StatementMargins
Gross margin is 45.87%, with operating and profit margins of -24.87% and -28.87%.
| Gross Margin | 45.87% |
| Operating Margin | -24.87% |
| Pretax Margin | -28.74% |
| Profit Margin | -28.87% |
| EBITDA Margin | -13.93% |
| EBIT Margin | -24.87% |
| FCF Margin | -5.60% |
Dividends & Yields
HCAT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.66% |
| Shareholder Yield | -5.66% |
| Earnings Yield | -18.61% |
| FCF Yield | -1.07% |
Analyst Forecast
The average price target for HCAT is $11.50, which is 49.74% higher than the current price. The consensus rating is "Buy".
| Price Target | $11.50 |
| Price Target Difference | 49.74% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HCAT has an Altman Z-Score of -1.23 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.23 |
| Piotroski F-Score | 2 |